Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1480 Systemic Treatment Sequences across Europe for Patients (pts) with Advanced Non-functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WD pNETs)

Introduction: Different systemic therapies (ST) are available for pts with advanced WD pNETs; however, the best treatment modalities and optimal sequencing are currently unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Custodio A

Authors: Custodio A, Van Adrichem R, Brizzi M, Heetfeld M, Jimenez-Fonseca P,

Keywords: pNET, treatment sequences,

#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study

Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heetfeld M, Rinke A, Borbath I, Crespo G, Olsen I,

Keywords: gastrointestinal cancer, neuroendocrine carcinoma, grade 3 NET, Ki-67, chemotherapy,

#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors

Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: olsen i

Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,

Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,

#568 Efficacy of Everolimus and Tolerability with Long-Term Use

Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Heetfeld M, Tischer E, Denecke T, Perez Fernandez C, Wiedenmann B,

Keywords: everolimus, prior therapies, pneumonitis ,